Piflufolastat F-18 Patent Expiration
Piflufolastat F-18 is Used for imaging and diagnosis of prostate cancer in men through PET scans. It was first introduced by Progenics Pharmaceuticals Inc
Piflufolastat F-18 Patents
Given below is the list of patents protecting Piflufolastat F-18, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pylarify | US10947197 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL | Jun 09, 2037 | Progenics Pharms Inc |
| Pylarify | US11851407 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL | Jun 09, 2037 | Progenics Pharms Inc |
| Pylarify | US8778305 | PSMA-binding agents and uses thereof | Sep 21, 2030 | Progenics Pharms Inc |
| Pylarify | US12070513 | PSMA-binding agents and uses thereof | Jul 31, 2029 | Progenics Pharms Inc |
| Pylarify | US9861713 | PSMA-binding agents and uses thereof | Jul 31, 2029 | Progenics Pharms Inc |
| Pylarify | US8487129 | Heterodimers of glutamic acid | Nov 07, 2027 | Progenics Pharms Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Piflufolastat F-18's patents.
Latest Legal Activities on Piflufolastat F-18's Patents
Given below is the list recent legal activities going on the following patents of Piflufolastat F-18.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Jul, 2025 | US9861713 |
| Notice of Final Determination -Election Required | 11 Jun, 2025 | US8778305 |
| Notice of Final Determination -Election Required | 11 Jun, 2025 | US9861713 |
| Notice of Final Determination -Election Required | 11 Jun, 2025 | US8487129 |
| Notice of Final Determination -Election Required | 06 Jun, 2025 | US8778305 |
| Notice of Final Determination -Election Required | 06 Jun, 2025 | US9861713 |
| Notice of Final Determination -Election Required | 06 Jun, 2025 | US8487129 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9861713 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8778305 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8487129 |
Piflufolastat F-18's Family Patents
